www.sec.gov 
The Pharma Data
DECEMBER 14, 2020
A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases.
The Pharma Data
JANUARY 26, 2021
The Registration Statement also contains a preliminary prospectus supplement relating to an “at-the-market” sales agreement, which the Company expects to enter into with B. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. capital markets. Riley Securities, Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 20, 2021
A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 19, 2021 and is available on the SEC’s website at www.sec.gov. The Company is developing a novel class of investigational antibody therapeutics, based on our Probody ® technology platform, for the treatment of cancer.
The Pharma Data
SEPTEMBER 8, 2020
Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.
Pfizer
FEBRUARY 16, 2023
While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.
The Pharma Data
SEPTEMBER 8, 2020
Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.
The Pharma Data
SEPTEMBER 9, 2020
On July 27, Pfizer and BioNTech announced that following extensive review of preclinical and clinical data from Phase 1/2 clinical trials, and in consultation with the FDA’s Center for Biologics Evaluation and Research (CBER) and other global regulators, the companies selected the BNT162b2 vaccine candidate to move forward into a Phase 2/3 study.
Expert insights. Personalized for you.
40 
Let's personalize your content